<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01469806</url>
  </required_header>
  <id_info>
    <org_study_id>04-400</org_study_id>
    <secondary_id>90-112</secondary_id>
    <nct_id>NCT01469806</nct_id>
  </id_info>
  <brief_title>Patello-Femoral Joint Post Market Clinical Follow-up Within the Knee Registry</brief_title>
  <acronym>PFJPMCF</acronym>
  <official_title>Zimmer(R) Gender Solutions(TM) Patello-Femoral Joint Prothesis Used Within the Knee Registry Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zimmer Biomet</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zimmer Biomet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the Registry is to allow for tracking of FDA approved and/or cleared
      knees used in primary, revision, unicompartmental or partial total knee arthroplasty (TKA).
      Second, it is our desire to assist orthopaedic surgeons in obtaining and evaluating
      radiographic and functional outcomes data on their PFJ patients using current published
      guidelines. Third, within this Registry, subsets of data on newer technology are being
      collected for the purpose of future publications. The Patello-Femoral Joint Post Market
      Clinical (PFJ PMCF) study is one such subset.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To obtain preoperative, operative and postoperative clinical outcomes data for the Zimmer
      Gender Solutions PFJ Knee Prosthesis used in primary partial knee arthroplasty such as knee
      scoring and patient satisfaction such collection using Patient Questionaire and SF-12 forms.
      Kaplan-Meir survivorship analysis of the device will be performed. Radiographic analysis of
      the device will also be performed at 1, 2, 3, 5, 7, and 10 year follow-up. It is planned that
      the resultant data will be pooled and published by the evaluating surgeons.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Suspended pending internal review/direction of the company's focus. No sites ever engaged or
    collected data.
  </why_stopped>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Long-term Device survivorship for publication</measure>
    <time_frame>10 Years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiographic analysis of enrolled subjects</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Arthritis</condition>
  <arm_group>
    <arm_group_label>1 - PFJ</arm_group_label>
    <description>Patients who require primary partial knee arthroplasty of the patello-femoral joint.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Zimmer Gender Solutions PFJ Knee Prosthesis</intervention_name>
    <description>Partial knee arthroplasty of the patello-femoral joint</description>
    <arm_group_label>1 - PFJ</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient has patellofemoral joint(s) affected by disease process and /or injury and
        qualifying for primary unilateral or bilateral replacement of the femoral trochlea based a
        primary diagnosis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is greater than 18 years of age;

          -  Patient selection is without bias to race or gender;

          -  Patient is in stable health and able to undergo surgery;

          -  Patient has patellofemoral joint(s) affected by disease process and/or injury and
             qualifying for primary unilateral or bilateral replacement of the femoral trochlea
             based a primary diagnosis of at least one of the following:

               -  Osteoarthritis

               -  Traumatic Arthritis

               -  Polyarthritis

               -  Severe Chondrocalcinosis

               -  Salvage of previously failed surgical attempts (e.g., arthroscopy, lateral
                  release, cartilage transplantation)

               -  History of patellar dislocation or patella fracture

               -  Dysplasia-induced patellofemoral degeneration

          -  Patient is willing and able to cooperate in prescribed post-operative therapy;

          -  Patient is willing and able to complete scheduled follow-up evaluations as described
             in the Informed Consent;

          -  Patient has participated in the Informed Consent process and has signed an IRB
             approved Informed Consent.

          -  Patient has not history of previous prosthetic replacement device(s) of any type in
             the affected knee joint;

          -  Independent of study participation, patient is scheduled to receive treatment using a
             Zimmer Gender Solutions Patellofemoral Joint Prosthesis (PFJ).

        Exclusion Criteria:

          -  Patient with an acute, chronic, local or systemic infection;

          -  Patient is skeletally immature;

          -  Patient is pregnant;

          -  Patient is a prisoner, mentally incompetent or anticipated to be non-compliant.
             Patient has a known allergy to one of the constituents of the implant, e.g. cobalt,
             chromium, nickel, etc.;

          -  Patient has Rheumatoid Arthritis (RA) AND an ulcer of the skin OR a history of
             recurrent breakdown of the skin;

          -  Patient has neuropathic arthropathy, neuromuscular disorder, neurologic condition,
             vascular disorder, systemic disease and/or other condition that affects lower limb
             function and/or could contribute to prosthesis instability, prosthesis fixation
             failure, and/or complications in postoperative care;

          -  Patient has a Body Mass Index (BMI) greater than 40;

          -  Patient has insufficient native bone stock in the operative joint (e.g. osteoporosis,
             osteonecrosis, tumors, cysts, etc.). Note: Bone void fillers are NOT considered native
             bone stock, even if autograft is used;

          -  Patient has severe instability, maltracking, or malalignment of the patella,
             patellofemoral, and/or tibiofemoral joints;

          -  Patient has patellectomy of the affected joint, including previous patellectomy,
             patellectomy performed simultaneous to study PFA, or scheduled patellectomy;

          -  Patient has insufficient menisci and/or ligament structures (e.g.
             non-functional/absent ACL and/or PCL);

          -  Patient exhibits tibiofemoral degeneration and/or Outerbridge grade greater than or
             equal to 3 in EITHER:

               -  one (medial or lateral) tibiofemoral compartment that is not treated with a
                  simultaneous compatible Zimmer unicompartmental knee replacement; OR

               -  both (medial AND lateral) tibiofemoral compartments, regardless of treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2011</study_first_submitted>
  <study_first_submitted_qc>November 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2011</study_first_posted>
  <last_update_submitted>September 26, 2016</last_update_submitted>
  <last_update_submitted_qc>September 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

